4D Molecular Therapeutics Inc (FDMT) — Capital Reinvestment Ratio
4D Molecular Therapeutics Inc (FDMT) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow ($28.55 Million) in capital expenditures ($631.00K). See debt-free asset ratio of 4D Molecular Therapeutics Inc to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
4D Molecular Therapeutics Inc Capital Reinvestment Ratio (2017–2017)
This chart tracks 4D Molecular Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check 4D Molecular Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for 4D Molecular Therapeutics Inc (2017–2017)
Year-by-year Capital Reinvestment Ratio for 4D Molecular Therapeutics Inc from 2017 to 2017. For live market cap and broader valuation context, see FDMT company net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2017 | 0.07x | $8.24 Million | $573.00K | — |